BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11598367)

  • 1. Complete response of a stage IV mucinous cystadenocarcinoma of the ovary to systemic chemotherapy employing paclitaxel and carboplatin.
    Yokoyama Y; Kaji H; Kondoh H; Takeuchi E; Yamasaki Y; Inui Y
    Gynecol Obstet Invest; 2001; 52(3):210-4. PubMed ID: 11598367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
    Gao KF; Liu FY; Chen FJ; Feng YL
    Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined chemotherapy with paclitaxel and carboplatin for mucinous cystadenocarcinoma of the ovary during pregnancy.
    Doi D; Boh Y; Konishi H; Asakura H; Takeshita T
    Arch Gynecol Obstet; 2009 Oct; 280(4):633-6. PubMed ID: 19205713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
    Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remarkable response of primary squamous cell carcinoma of the ovary to paclitaxel and cisplatin.
    Eltabbakh GH; Hempling RE; Recio FO; O'Neill CP
    Obstet Gynecol; 1998 May; 91(5 Pt 2):844-6. PubMed ID: 9572185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience.
    Alexandre J; Ray-Coquard I; Selle F; Floquet A; Cottu P; Weber B; Falandry C; Lebrun D; Pujade-Lauraine E;
    Ann Oncol; 2010 Dec; 21(12):2377-2381. PubMed ID: 20494964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A multicenter randomized clinical trial of weekly paclitaxel and carboplatin vs three weeks paclitaxel and carboplatin as first line chemotherapy in epithelial ovarian cancer].
    Shen K; Li MD; Feng YJ; Ma D; Li ZT; Xie X; Kong BH; Cui H; Song L; Peng ZL; Li L; Wu M; Chen YL; Lui JH; Wu LY; Lang JH;
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2099-103. PubMed ID: 16313817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer.
    Vapattanawong P
    J Med Assoc Thai; 2006 Sep; 89(9):1357-61. PubMed ID: 17100369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
    Gordon AN; Asmar L; Messing MJ; Street DG; Pippitt CH; Bailey CL; Savage J; Young JA
    Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomyxoma Peritonei arising from a mucinous borderline ovarian tumour: Case report and literature review.
    Saluja M; Kenwright DN; Keating JP
    Aust N Z J Obstet Gynaecol; 2010 Aug; 50(4):399-403. PubMed ID: 20716272
    [No Abstract]   [Full Text] [Related]  

  • 12. A case of rapidly growing ovarian squamous cell carcinoma successfully controlled by weekly paclitaxel-carboplatin administration.
    Ohtani K; Sakamoto H; Masaoka N; Shimada K; Kanaeda T; Kurihara M; Nagai N; Satoh K
    Gynecol Oncol; 2000 Dec; 79(3):515-8. PubMed ID: 11104632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer.
    Méndez LE; Mueller A; Salom E; González-Quintero VH
    Obstet Gynecol; 2003 Nov; 102(5 Pt 2):1200-2. PubMed ID: 14607056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
    Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
    Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Paclitaxel + carboplatin (TC)-resistant stage Ic squamous cell carcinomas arising in mature cystic teratomas of the ovary].
    Ishikawa M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Miyazaki K
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):747-52. PubMed ID: 20414041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
    Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucinous cystadenocarcinoma with sarcoma-like mural nodules arising in a mature cystic teratoma of the ovary: a case report.
    Mizuno K; Hirata S; Kasai T; Yasumizu T; Kato J
    J Obstet Gynaecol Res; 1996 Oct; 22(5):461-5. PubMed ID: 8987329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93).
    Schink JC; Weller E; Harris LS; Cella D; Gerstner J; Falkson C; Wadler S
    Cancer J; 2001; 7(2):155-64. PubMed ID: 11324769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and prognosis of mucinous tumors of the ovary.
    Kikkawa F; Nawa A; Kajiyama H; Shibata K; Ino K; Nomura S
    Gynecol Oncol; 2006 Oct; 103(1):171-5. PubMed ID: 16546243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.